# *Brings you the latest on*
# Sexually Transmitted Diseases!

***Sexually Transmitted Diseases*** is your resource for the most current, comprehensive information available on all aspects of sexually transmitted disease. Its unique, multidisciplinary perspective provides insight into the latest advances in . . .

- **Diagnosis and Treatment**
- **Epidemiology**
- **Etiology**
- **Microbiology**
- **Public Health and Behavior**
- **Pathology**




Published bi-monthly, ***Sexually Transmitted Diseases*** brings you original articles on newly identified syndromes, new investigations into the mechanism of disease, descriptions of clinical experiences and reports on therapeutic trials. Features include notes from the CDC, NIH and ASHA, case reports and AVDA news.

Journal of the American Venereal Disease Association
**Julius Schachter, PhD, Editor**

***NO-RISK GUARANTEE!*** If you're not completely satisfied, you may cancel your subscription at any time and receive a refund for all unmailed issues.

## IT'S EASY TO ORDER!

| **CALL TOLL-FREE:** | **FAX:** | **INTERNET:** | **WORLD WIDE WEB:** | **E-mail:** |
|---|---|---|---|---|
| 800-777-2295;<br>301-714-2300<br>(outside the U.S. and Canada) | 301-824-7390 | gopher:infor.com 5200 and gopher:infor.com 5300 | http://www.lrpub.com/lrpub/ | lrorders@phl.lrpub.com |

Published bi-monthly. Annual subscription rates:
Individual $150.00 (U.S.) - $160.00 (Other countries)
Institution $200.00 (U.S.) - $245.00 (Other countries)

**Order directly from Lippincott-Raven, your local medical bookseller, or publisher representative.**

Published by
**Lippincott - Raven**
PUBLISHERS

A **Wolters Kluwer** Company
227 East Washington Square
Philadelphia, PA 19106-3780

DMZ55666



'Engerix B' isn't just something for the weekend. It provides up to five years' protection against hepatitis B; which means you don't have to rely on your patients using a condom every time they have sex.

So who's at risk? People who are sexually active, either with multiple partners, or who travel abroad and have casual, unprotected sex.

The fact is hepatitis B can be contracted in the same way as AIDS, but it's 100 times more infectious. Worst still, it has been found in body fluids such as sweat, saliva, even tears.

It's quite reassuring to know then that, world-wide, 'Engerix B' has protected more people against the hepatitis B virus than any other vaccine.

You can order 'Engerix B' in pre-filled syringes, by calling SmithKline Beecham on 0181-913 4290. So, even if you can't prevent your patients from picking up every sexually transmitted disease, you can give them five years' protection against hepatitis B.

**Contra-indications:** Hypersensitivity to any component of the vaccine. Severe febrile infections.
**Precautions:** Response may be impaired in renal dialysis patients or those who are immunocompromised. Adrenaline 1:1000 should be available in case of anaphylaxis. Use in pregnancy: see Data Sheet.
**Adverse reactions:** Mild transient local soreness, erythema and induration at the injection site. Occasionally low grade fever, malaise, fatigue, arthralgia, arthritis, myalgia, headache, dizziness, syncope, nausea, vomiting, diarrhoea, abdominal pain, lymphadenopathy, abnormal liver function tests, rashes rarely with urticaria. Exceptionally, severe skin disorders such as *erythema multiforme*. Very rarely one week or more after injection, transient arthralgia, pruritus or urticaria, but no causal relationship established.
Neurological manifestations in temporal association with the vaccine, including very rarely paraesthesia and extremely rarely paralysis, neuropathy and neuritis (including Guillain-Barré syndrome, optic neuritis and multiple sclerosis). No causal relationship established.
Early onset allergic-type reactions reported rarely.
**Legal category** POM. 11.8.94.

'Engerix B' is a trade mark.



ENGERIX B
**Hepatitis B Vaccine (rby)**

0695 EB:AD/5/051

# Erectile dysfunction? Now there are TWO licensed injectable treatments...

NEW




# both available in the same complete, convenient presentation




Now Caverject, the only injectable therapy licensed for erectile dysfunction in the U.K., is available in a 10 microgram as well as a 20 microgram presentation.

Over 50% of patients in a self injection study responded to doses of 10 micrograms or less of alprostadil[1], so the new presentation will be the logical choice for many of your patients, cutting wastage and making dose adjustment simpler.



## Caverject▼

**alprostadil**

## A solution that works

For prescribing information see data sheet.

**CAVERJECT POWDER FOR INJECTION ▼**

Alprostadil

**Presentation**

White to off-white lyophilised powder, containing alprostadil 10 or 20 micrograms. Also contains lactose and sodium citrate. Diluent is 1 ml bacteriostatic water for injections (benzyl alcohol 0.9% w/v).

**Uses**

Treatment of erectile dysfunction.

An adjunct to other diagnostic tests in the diagnosis of erectile dysfunction.

**Dosage and Administration**

Diagnosis: 5-10 micrograms where there is evidence of neurologic dysfunction. 20 micrograms in other cases.

Treatment: neurogenic dysfunction - initial dose 1.25 micrograms. Second dose 2.5 micrograms, third 5 micrograms, and subsequent incremental increases of 5 micrograms until an optimal dose is achieved. Non-neurogenic dysfunction - initial dose 2.5 micrograms. Second dose 5 micrograms if partial response and 7.5 micrograms if no response. Subsequent increments 5-10 micrograms until optimal dose achieved. If no response, next higher dose can be given in 1 hour; if partial response there must be at least a 1-day interval. The usual dose is 10-20 micrograms. Maximum dose 60 micrograms. The recommended frequency of injection is no more than once daily and no more than three times weekly.

The first injection of alprostadil must be done by medically trained personnel. After proper training and instruction, alprostadil may be self-injected.

The dose should provide the patient with an erection that is satisfactory for sexual intercourse. It is recommended that the dose administered produces a duration of the erection not exceeding one hour.

**Contra-indications, warnings, etc**

*Contra-indications:* Known hypersensitivity to alprostadil, benzyl alcohol, or any of the other constituents. Sickle cell anaemia or trait, multiple myeloma, or leukaemia (risk of priapism). Patients with a penile implant or anatomical deformity of the penis such as angulation, cavernosal fibrosis, or Peyronie's disease.

*Warnings:* Prolonged erection and/or priapism. Patients with an erection lasting 4 hours or more should report to a physician for consideration of detumescent therapy.

Painful erection is more likely to occur in patients with anatomical deformations of the penis. Regularly follow-up to detect penile fibrosis. Discontinue treatment where penile angulation, cavernosal fibrosis, or Peyronie's disease develops.

Patients on anticoagulants such as warfarin or heparin may have increased propensity for bleeding after the intracavernous injection.

Diagnose and treat underlying medical causes of erectile dysfunction before using Caverject.

Use of intracavernous alprostadil offers no protection from the transmission of sexually transmitted diseases. Individuals should be counselled about the spread of sexually transmitted diseases, including HIV.

*Pregnancy and lactation:* Not applicable. (High doses of alprostadil (0.5 to 2.0 mg/kg subcutaneously) had an adverse effect on the reproductive potential of male rats, although this was not seen with lower doses (0.05 to 0.2 mg/kg). Alprostadil did not affect rat spermatogenesis at doses 200 times greater than the proposed human intrapenile dose.)

*Side-effects:* Pain in the penis, mainly mild or moderate in intensity (34%). 3% of patients discontinued treatment due to pain. Haematoma at the site of injection (3%). Prolonged erection (2%); priapism (0.5%). Injection site ecchymosis, penile rash, penile oedema, penile fibrosis (1-1.5%). Other local (eg balanitis, injection site reactions, phimosis, venous leak, abnormal ejaculation,) and systemic events (eg urinary urgency or impairment, vasodilatation, hypotension, hypertension, supraventricular extrasystole, dizziness, headache, pelvic pain) were reported by fewer than 1% of patients.

*Interactions:* None known. Not intended for co-administration with any other agent for the treatment of erectile dysfunction.

*Incompatibilities:* Not known. Only the supplied diluent should be used to prepare solutions.

**Pharmaceutical precautions**

Caverject must be stored in a refrigerator until dispensed. May then be stored below 25°C for up to 3 months. Reconstituted solutions should be used immediately and not stored. Do not store the unused pack or reconstituted solution in a freezer.

**Legal category** POM

**Package quantities**

Single packs containing a vial of Caverject powder and a syringe of diluent.

**Product licence numbers**

PL 0032/0203 Caverject Powder for Injection 10 micrograms
PL 0032/0188 Caverject Powder for Injection 20 micrograms
PL 0032/0193 Bacteriostatic Water for Injections diluent

**Holder of product licences**

Upjohn Limited, Fleming Way, Crawley, West Sussex, RH10 2LZ.

**Date of preparation or last review** January 1996

**Pricing information**

£7.70 per 10 microgram pack, £9.95 per 20 microgram pack.

**Reference:** Schramek P et al., *Br J Urol* 1990; **65**: 68-71

Date of preparation: January 1996

Registered trademark: Caverject. CV3248UK

**Pharmacia & Upjohn**

Davy Avenue, Knowlhill, Milton Keynes, Bucks MK5 8PH.

# How to do it even better!

**The highly popular *How To Do It* series is a collection of expert advice on an enormous range of topic that doctors need to know about that are not necessarily covered in formal training.**

**All three volumes have now been completely updated, with new chapters, and a user friendly format where subjects are grouped into themes. Whether you want to chair a committee, improve your counselling skills with cancer patients, or even survive a formal dinner, your questions will be answered in these entertaining and practical guides.**

**A must for all doctors, from students through to the retired.**










**How to Do It Volume 1**
**● Management ● Employment ● Counselling**
**ISBN 0 7279 0848 0 272 pages April 1995**
**UK £12.95; Overseas £15.00**
**(BMA members £11.95; £14.00)**

**How to Do It Volume 2**
**● Examinations ● Academia ● Research and Communication**
**ISBN 0 7279 0895 2 240 pages April 1995**
**UK £12.95; Overseas £15.00**
**(BMA members £11.95; £14.00)**

**How to Do It Volume 3**
**● Writing ● Publishing and Publicity ● Something Different**
**ISBN 0 7279 0896 0 264 pages April 1995**
**UK £12.95; Overseas £15.00**
**(BMA members £11.95; £14.00)**

## Purchase the complete set at a reduced price!

**ISBN 0 7279 0906 1 UK £34.95; Overseas £39.00 (BMA members £31.95; £36.00)**




BMJ Publishing Group

**Also available: How to Write a Paper Edited by G M Hall**

**"Highly recommended as a practical and readable guide to getting published."**
*Journal of the Institute of Health Education*

**ISBN 0 7279 0822 7 128 pages 1994 UK £8.95; Overseas £11.00 (BMA members £8.45; £10.50)**

## Order Form

Available from: **BMJ Publishing Group, P.O. Box 295, London WC1H 9TE, (Tel: 0171 383 6185/6245), medical booksellers or the BMJ bookshop in BMA House**

Please send me _____ copy/ies of HOW TO DO IT VOLUME 1

Please send me _____ copy/ies of HOW TO DO IT VOLUME 2

Please send me _____ copy/ies of HOW TO DO IT VOLUME 3

Please send me _____ COMPLETE SET/S OF HOW TO DO IT

Please send me _____ copy/ies of HOW TO WRITE A PAPER

BMA Membership No. _____

Name _____
(Print Clearly)

Address _____

_____

_____ Postcode _____

Cheque enclosed (made payable to British Medical Journal) £ _____

Debit my AMERICAN EXPRESS/VISA/MASTERCARD

Card No. _____ Exp _____

Signature _____

❑ Please send me a BMJ PUBLISHING GROUP CATALOGUE

# NEW WARTICON CREAM


# La Crème de la Crème

New Warticon Cream is the first ever podophyllotoxin cream for the self-treatment of genital warts.

The cream combines the well proven efficacy [1] and good tolerability [2] of podophyllotoxin in an easy to use formulation.

Men and women will find that new Warticon Cream, with its discreet tube and simple application, adds convenience and dignity to the self-treatment of genital warts.

**NEW**
**Warticon®**
***cream***

Podophyllotoxin 0.15% w/w

## The cream of self-treatment for genital warts

**Abbreviated Prescribing Information**
**Warticon Cream Presentation:** White homogeneous cream containing 0.15% w/w podophyllotoxin. **Uses:** For the topical treatment of condyloma acuminata affecting the penis, and the female external genitalia. **Dosage and Administration:** The affected area should be thoroughly washed with soap and water, and dried prior to application. Using a fingertip, Warticon Cream is applied twice daily for 3 days using only enough cream to just cover each wart. The hands should be thoroughly washed after each application. Residual warts should be treated with further courses of twice daily applications for 3 days at weekly intervals, if necessary, for a total of 4 weeks of treatment. Where lesions are greater in area than 4cm² it is recommended that treatment takes place under the direct supervision of medical staff. **Contraindications, Warnings etc:** Open wounds, hypersensitivity to podophyllotoxin. Avoid contact with the eyes. In the event of the preparation entering the eye, the eye should be thoroughly bathed in water. Prolonged contact with healthy skin should be avoided, as the cream contains an active pharmaceutical substance that could be harmful to healthy skin. **Side Effects:** Local irritation may occur on second or third day of application associated with the start of wart necrosis. In the majority of cases the reactions are mild (see Data Sheet). **Use in Pregnancy:** Do not use during pregnancy or lactation. **Overdosage:** There have been no reported overdosages with Warticon Crea No specific antidote is known. In the event of accidental ingestion give emetic or stomach washout Treatment should be symptomatic and in severe oral overdose ensure the airway is clear and give fluids, check and correct electrolyte balance, monitor blood gases and liver function. Blood count should be monitored for at least five days. **Pharmaceutical Precautions:** Product should be stored room temperature. **Legal Category:** POM. **Package Quantities:** Single tube containing 5g of Warti Cream. The pack also contains a mirror to facilitate accurate application. **Basic NHS Price:** Wartico Cream 5g £17.40. **Product Licence Number:** PL 3863/0010. **Date of Preparation:** March 1995.

**References:** 1. Kinghorn, G. et al. International Journal of STD & AIDS 1993; 4: 194-199.
2. Strand, A. et al. 1995 In press

Perstorp Pharma Further information is available from: Perstorp Pharma Ltd, Intec 2, Wade Road, Basingstoke, Hants RG24 8NE. Tel: 01256 477868. Fax: 01256 215

and Warticon are registered tradema